Medicus Pharma Ltd美股招股说明书(2025-07-23版)

This prospectus supplement amends and supplements the prospectus dated effective April 10, 2025, as supplemented or amended fromtime to time (the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333- 279771). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference inthe Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on July 23, 2025 (the "Form 8-K"). Accordingly, we have attached the Form 8-K to this prospectus supplement. supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in theProspectus and this prospectus supplement, you should rely on the information in this prospectus supplement.Our common shares and warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"),are listed on The Nasdaq Capital Market ("Nasdaq") under the symbols "MDCX" and "MDCXW," respectively. On July 22, 2025, thelast reported sales prices of the common shares and Public Warrants were $3.08 and $1.05, respectively. We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible forreduced public company disclosure requirements.Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described None of the Securities and Exchange Commission, any state securities commission or the securities commission of anyCanadian province or territory has approved or disapproved of the securities offered by this prospectus supplement or theProspectus or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to thecontrary is a criminal offense. The date of this prospectus supplement is July 23, 2025. UNITED STATESSECURITIES AND EXCHANGE COMMISSION ___________________________FORM 8-K CURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 MEDICUS PHARMA LTD.(Exact name of registrant as specified in its charter) If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ ForWithhold William L. Ashton10,115,63917,036N/A3,185,015Dr. Raza Bokhari10,115,36417,311N/A3,185,015Robert J. Ciaruffoli10,115,63917,036N/A3,185,015 Hon. Cathy McMorris Rodgers10,115,03917,636N/A3,185,01510,116,51916,156N/A3,185,015 Proposal 5. Shareholders approved the proposal to amend the Articles to increase the voting threshold required to remove theChairman of the Board to a vote of at least 75% of the Board and to make this provision part of the Articles, which required theaffirmative vote of at least two-thirds of the votes cast by the shareholders present at the Meeting in person or by proxy: 9,891,337241,338N/A SIGNATUREPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on /s/ Raza BokhariDr. Raza BokhariExecutive Chairman and Chief Executive Officer